Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.33

Mkt cap

1.7M

Volume

200

High

0.34

P/E Ratio

N/A

52-wk high

38.00

Low

0.33

Div yield

N/A

52-wk low

0.30

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Neutral rating on Panbela Therapeutics (OTC:PBLA).

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 10:15 am

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Neutral rating on Panbela Therapeutics (OTC:PBLA).

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 5:06 pm

HC Wainwright & Co. has downgraded Panbela Therapeutics from Buy to Neutral, as per analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 5:31 pm

Panbela Therapeutics (NASDAQ:PBLA) reported a Q1 2024 GAAP EPS of $(2.28), significantly missing the analyst consensus estimate of $(1.48) by 54.05%.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 8:21 pm

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Panbela Therapeutics (PBLA) but lowers the price target from $16 to $5.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:49 pm

Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Panbela Therapeutics (PBLA) and kept the price target at $25.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 3:59 pm

Panbela Therapeutics (OTC:PBLA) reported Q4 earnings with an EPS of $-65.9, missing estimates by -171.0% and showing no revenue change from the previous year. Despite past earnings misses leading to share price increases, this significant miss could impact investor sentiment.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 8:55 pm

Panbela Therapeutics (NASDAQ:PBLA) reported a Q4 2023 GAAP EPS loss of $(65.90), significantly missing the analyst consensus estimate of $(24.34) by 170.75%.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 8:51 pm

Panbela Therapeutics (NASDAQ:PBLA) is scheduled to release its quarterly earnings report on March 26, 2024, with an estimated EPS of $-24.34. Historical data shows mixed reactions to past earnings reports, with the last quarter missing EPS estimates and resulting in a 2.66% share price increase the following day. Over the past year, PBLA shares have declined by 99.79%, indicating significant investor concern ahead of this earnings announcement.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

The article highlights the top 4 oversold health care stocks with an RSI near or below 30, indicating potential undervaluation. These include ProSomnus, Inc. (OSA), Panbela Therapeutics, Inc. (PBLA), Sintx Technologies, Inc. (SINT), and GRI Bio, Inc. (GRI). Each company has experienced significant stock price declines recently but shows signs of potential short-term recovery.

Portfolio Pulse from Avi Kapoor

February 23, 2024 | 12:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.